We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
(+32%)
Cap. Flow
+$142M
Cap. Flow
% of AUM
5.42%
Top 10 Holdings %
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33
Avg Time Held Equity + Options
4.2
quarters
Top 10 Avg Time Held Equity + Options
5.4
quarters
Top 20 Avg Time Held Equity + Options
5.4
quarters
Avg Time Held Equity only
4.4
quarters
Top 10 Avg Time Held Equity only
5.4
quarters
Top 20 Avg Time Held Equity only
5.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$64.1M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$36.1M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$31.4M |
| 4 |
Puma Biotechnology
PBYI
|
+$17.7M |
| 5 |
Cymabay Therapeutics
CBAY
|
+$15.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$42.4M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$36.7M |
| 3 |
Radius Health, Inc.
RDUS
|
+$29.2M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$20.9M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.22% |
| 2 | Miscellaneous | 1.22% |
| 3 | Industrials | 0.33% |
| 4 | Consumer Staples | 0.16% |
| 5 | Consumer Discretionary | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
argenx
ARGX
$51.1B
| $10.1M | 0.39% |
450,000
| – | – |
2017 Q2
1 quarter
|
|
52
uniQure
QURE
$1.51B
| $9.98M | 0.38% |
1,040,119
-50,000
| -5% | -$402K |
2014 Q4
11 quarters
|
|
|
ABMD
53
DELISTED
Abiomed Inc
ABMD
| $8.72M | 0.33% |
+51,729
| New | +$7.82M |
2017 Q3
0 quarters
|
|
|
ATHN
54
DELISTED
Athenahealth, Inc.
ATHN
| $8.71M | 0.33% |
+70,000
| New | +$9.64M |
2017 Q3
0 quarters
|
|
55
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $8.53M | 0.33% |
+363,175
| New | +$4.07M |
2017 Q3
0 quarters
|
|
56
UroGen Pharma
URGN
$1.87B
| $8.48M | 0.32% |
269,014
| – | – |
2017 Q2
1 quarter
|
|
|
OXFD
57
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $7.82M | 0.3% |
465,356
+421,250
| +955% | +$6.86M |
2017 Q2
1 quarter
|
|
58
Ardelyx
ARDX
$834M
| $7.57M | 0.29% |
1,352,391
-458,190
| -25% | -$2.41M |
2014 Q3
12 quarters
|
|
59
Sonida Senior Living
SNDA
$1.74B
| $7.03M | 0.27% |
37,345
+2,000
| +6% | +$393K |
2014 Q4
11 quarters
|
|
60
DELISTED
Exact Sciences
EXAS
| $6.38M | 0.24% |
135,444
+35,444
| +35% | +$1.43M |
2017 Q1
2 quarters
|
|
|
CMTA
61
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $6.29M | 0.24% |
+352,250
| New | +$5.76M |
2017 Q3
0 quarters
|
|
|
FOMX
62
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $6.2M | 0.24% |
1,117,324
| – | – |
2016 Q2
5 quarters
|
|
63
Zymeworks
ZYME
$1.82B
| $5.83M | 0.22% |
730,768
| – | – |
2017 Q2
1 quarter
|
|
64
Talphera
TLPH
$56.1M
| $5.72M | 0.22% |
62,230
-124,337
| -67% | -$7.75M |
2013 Q2
17 quarters
|
|
|
SRRA
65
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $5.67M | 0.22% |
91,380
| – | – |
2017 Q1
2 quarters
|
|
66
Heron Therapeutics
HRTX
$78.9M
| $5.33M | 0.2% |
+330,000
| New | +$5.18M |
2017 Q3
0 quarters
|
|
|
ICPT
67
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $5.22M | 0.2% |
+90,000
| New | +$9.69M |
2017 Q3
0 quarters
|
|
68
DELISTED
Clearside Biomedical
CLSD
| $5.15M | 0.2% |
41,345
| – | – |
2016 Q2
5 quarters
|
|
69
Zai Lab
ZLAB
$2.76B
| $4.72M | 0.18% |
+175,000
| New | +$4.88M |
2017 Q3
0 quarters
|
|
|
OMED
70
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $4.69M | 0.18% |
+1,038,289
| New | +$4.21M |
2017 Q3
0 quarters
|
|
|
ARAV
71
DELISTED
Aravive, Inc. Common Stock
ARAV
| $4.63M | 0.18% |
314,693
-419,860
| -57% | -$42.4M |
2014 Q1
14 quarters
|
|
72
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $4.58M | 0.18% |
+50,000
| New | +$3.83M |
2017 Q3
0 quarters
|
|
73
Merit Medical Systems
MMSI
$5.36B
| $4.24M | 0.16% |
+100,000
| New | +$4.03M |
2017 Q3
0 quarters
|
|
74
DELISTED
Molecular Templates, Inc.
MTEM
| $4.23M | 0.16% |
+48,276
| New | +$4.17M |
2017 Q3
0 quarters
|
|
|
NEPT
75
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $4.11M | 0.16% |
4,657
| – | – |
2013 Q2
17 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q3 2017 Portfolio in Review
As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Perceptive Advisors deployed $142M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.
- Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
- Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
- Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
- Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
- Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
- Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
- Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.
Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.